Polymorphisms in the thrombopoietin gene are associated with risk of myocardial infarction at a young age.

[1]  M. Sanada,et al.  Familial essential thrombocythemia associated with one-base deletion in the 5'-untranslated region of the thrombopoietin gene. , 1998, Blood.

[2]  H. Handa,et al.  Characterization of the Human Thrombopoietin Gene Promoter , 1997, The Journal of Biological Chemistry.

[3]  Y. Hong,et al.  Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[4]  D. Martincic,et al.  Improved detection of p53 point mutations by dideoxyfingerprinting (ddF). , 1996, Oncogene.

[5]  S. Humphries,et al.  PCR induction of a TaqI restriction site at any CpG dinucleotide using two mismatched primers (CpG-PCR). , 1996, Genome research.

[6]  J. Jones,et al.  Myocardial infarction in young adults: risk factors and clinical features. , 1996, The Journal of emergency medicine.

[7]  F. D. de Sauvage,et al.  Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin , 1996, The Journal of experimental medicine.

[8]  S. Humphries,et al.  High-throughput genotyping using horizontal polyacrylamide gels with wells arranged for microplate array diagonal gel electrophoresis (MADGE). , 1995, BioTechniques.

[9]  S. Humphries,et al.  High-throughput method for determination of apolipoprotein E genotypes with use of restriction digestion analysis by microplate array diagonal gel electrophoresis. , 1995, Clinical chemistry.

[10]  W. Vainchenker,et al.  The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. , 1995, Blood.

[11]  S. Humphries,et al.  The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM Study , 1995, Thrombosis and Haemostasis.

[12]  L. Fisher,et al.  Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). , 1995, Journal of the American College of Cardiology.

[13]  K. Kaushansky.  Thrombopoietin: the primary regulator of platelet production. , 1995, Blood.

[14]  G. P. Weavind,et al.  Utilities for high throughput use of the single strand conformational polymorphism method: screening of 791 patients with familial hypercholesterolaemia for mutations in exon 3 of the low density lipoprotein receptor gene. , 1995, Journal of medical genetics.

[15]  V. Broudy,et al.  Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Hamsten,et al.  Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Sommer,et al.  Restriction endonuclease fingerprinting (REF): a sensitive method for screening mutations in long, contiguous segments of DNA. , 1995, BioTechniques.

[18]  AL Gurney,et al.  Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. , 1995, Blood.

[19]  J. Shutter,et al.  Cloning and Characterization of the Human Megakaryocyte Growth and Development Factor (MGDF) Gene (*) , 1995, The Journal of Biological Chemistry.

[20]  F. Grant,et al.  Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  N. Seki,et al.  Molecular cloning and chromosomal localization of the human thrombopoietin gene , 1994, FEBS letters.

[22]  A. Gurney,et al.  Thrombocytopenia in c-mpl-deficient mice. , 1994, Science.

[23]  V. Broudy,et al.  Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin , 1994, Nature.

[24]  D. Goeddel,et al.  Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand , 1994, Nature.

[25]  G. Thomas,et al.  Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation polymorphism in the detection of mutations in exons 5 to 8 of the p53 gene. , 1994, Oncogene.

[26]  D. Levin,et al.  Limitations in the use of SSCP analysis. , 1993, Mutation research.

[27]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[28]  J. Erusalimsky,et al.  The regulation of megakaryocyte polyploidization and its implications for coronary artery occlusion , 1993, European journal of clinical investigation.

[29]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[30]  M. Burr,et al.  Influence of platelet size on outcome after myocardial infarction , 1991, The Lancet.

[31]  J. Erikssen,et al.  Blood Platelet Count and Function Are Related to Total and Cardiovascular Death in Apparently Healthy Men , 1991, Circulation.

[32]  J. Schapiro,et al.  Platelet hyperreactivity and prognosis in survivors of myocardial infarction. , 1990, The New England journal of medicine.

[33]  J. Yudkin,et al.  Increased mean platelet volume after acute myocardial infarction relates to diabetes and to cardiac failure. , 1988, Diabetes research and clinical practice.

[34]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[35]  S. Willich,et al.  Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. , 1987, The New England journal of medicine.

[36]  L Roy,et al.  Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.

[37]  J. Martin,et al.  Shortened bleeding time in acute myocardial infarction and its relation to platelet mass. , 1985, British medical journal.

[38]  K. Buetow,et al.  Nonuniform recombination within the human beta-globin gene cluster. , 1984, American journal of human genetics.

[39]  H. A. Cameron,et al.  Platelet size in myocardial infarction. , 1983, British medical journal.

[40]  J. Martin,et al.  Changes in volume and density of platelets in myocardial infarction. , 1983, British medical journal.

[41]  R. Skoda,et al.  An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia , 1998, Nature Genetics.

[42]  J. Cooper,et al.  The Effects of Quality and Timing of Venepuncture on Markers of Blood Coagulation in Healthy Middle-aged Men , 1995, Thrombosis and Haemostasis.

[43]  P. Talmud,et al.  European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender-genotype-environment interaction. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[44]  P. Elwood,et al.  Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. , 1991, Circulation.

[45]  J. L. Gordon.  Platelets in Biology and Pathology , 1981 .